MetaCap

Protalix BioTherapeutics (DE) (PLX) vs SAB Biotherapeutics (SABS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Protalix BioTherapeutics (DE) (PLX) has outperformed SAB Biotherapeutics (SABS) over the past year, gaining 65.7% versus a loss of 28.9%. Over five years, PLX leads with a +192.9% price change compared with -97.3% for SABS. SAB Biotherapeutics is the larger company by market cap ($253.1 million vs $244.5 million), about 1.0 times the size, while Protalix BioTherapeutics (DE) is growing revenue faster (-1.2% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PLX+65.71%SABS-28.86%
+86%+22%-43%
Nov 21, 20251 yearNov 20, 2026
PLX+195.92%SABS-97.45%
+250%+67%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PLX versus SABS key metrics
MetricPLXSABS
Share price$2.90$2.81
Market cap$244.52M$253.15M
1-day change-5.23%-3.44%
YTD return+61.11%-24.87%
1-year return+65.71%-28.86%
5-year return+192.93%-97.32%
P/E ratio (TTM)12.08—
Forward P/E4.68—
EPS (TTM)$0.24$-1.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$52.74M$0
Revenue growth (YoY)-1.23%-100.00%
Net income (latest FY)$-6.60M$13.27M
Gross margin48.82%—
Operating margin-10.43%—
Net margin-12.52%—
52-week high$3.19$5.15
52-week low$1.65$2.44
Distance from 52-week high-9.09%-45.44%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+313.79%+314.23%
Average volume903.48K633.60K
Shares outstanding84.32M90.09M
Employees22686
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PLX has outperformed SABS by 94.6 percentage points over the past year.
  • Protalix BioTherapeutics (DE) grew revenue faster in its latest fiscal year (-1.23% vs -100.00%).

About Protalix BioTherapeutics (DE)

PLX stock →

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees

About SAB Biotherapeutics

SABS stock →

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees

PLX vs SABS FAQ

Which is bigger, Protalix BioTherapeutics (DE) or SAB Biotherapeutics?

SAB Biotherapeutics (SABS) is larger, with a market capitalization of $253.15M compared with $244.52M for Protalix BioTherapeutics (DE) (PLX).

Which stock has performed better over the past year, PLX or SABS?

PLX returned +65.71% over the past 12 months, compared with -28.86% for SABS (price return, excluding dividends). Past performance does not predict future results.

Are Protalix BioTherapeutics (DE) and SAB Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons